Comparison of clinical leukemia specimens obtained and analyzed
| . | Samples obtained . | Samples analyzed in present study . |
|---|---|---|
| AML | ||
| Number of patients | 140 | 42 |
| FAB classification | ||
| M0 | 3 | 1 |
| M1 | 17 | 9 |
| M2 | 34 | 10 |
| M3 | 11 | 1 |
| M4 | 33 | 7 |
| M5 | 17 | 8 |
| M6 | 16 | 4 |
| M7 | 9 | 2 |
| Treatment | ||
| Timed sequential Ac-D-X* | 129 | 38 |
| Individual therapy | 8 | 2 |
| No treatment | 3 | 2 |
| Age, median (range) | 52 (18-79) | 56 (18-79) |
| WBC, median (range) | 4800 (400-313 000) | 9400 (800-258 000) |
| AHD†, no. (%) | 32 (22%) | 8 (19%) |
| Secondary leukemia‡, no. (%) | 16 (11%) | 2 (5%) |
| CD34-positive, no. (%) | 85/135 (63%) | 30/42 (71%) |
| Poor risk karyotype1-153, no. (%) | 58/131 (44%) | 21/38 (55%) |
| % blasts in analyzed sample, median | 67 | 88 |
| CR with first cycle, no. (%)1-155 | 80/116 (69%) | 18/34 (53%) |
| ALL | ||
| Number of patients | 29 | 18 |
| T-cell phenotype, no. (%) | 10 (34) | 5 (28) |
| Age, median (range) | 34 (18-74) | 29 (18-74) |
| WBC × 10−3, median (range) | 26 (0.8-600) | 46 (3-312) |
| Ph1chromosome, no. (%) | 7/28 (25) | 2/17 (12) |
| % blasts, median | 85 | 88 |
| CR by day 60, no. (%)1-155 | 11/21 (52%) | 9/12 (75%) |
| . | Samples obtained . | Samples analyzed in present study . |
|---|---|---|
| AML | ||
| Number of patients | 140 | 42 |
| FAB classification | ||
| M0 | 3 | 1 |
| M1 | 17 | 9 |
| M2 | 34 | 10 |
| M3 | 11 | 1 |
| M4 | 33 | 7 |
| M5 | 17 | 8 |
| M6 | 16 | 4 |
| M7 | 9 | 2 |
| Treatment | ||
| Timed sequential Ac-D-X* | 129 | 38 |
| Individual therapy | 8 | 2 |
| No treatment | 3 | 2 |
| Age, median (range) | 52 (18-79) | 56 (18-79) |
| WBC, median (range) | 4800 (400-313 000) | 9400 (800-258 000) |
| AHD†, no. (%) | 32 (22%) | 8 (19%) |
| Secondary leukemia‡, no. (%) | 16 (11%) | 2 (5%) |
| CD34-positive, no. (%) | 85/135 (63%) | 30/42 (71%) |
| Poor risk karyotype1-153, no. (%) | 58/131 (44%) | 21/38 (55%) |
| % blasts in analyzed sample, median | 67 | 88 |
| CR with first cycle, no. (%)1-155 | 80/116 (69%) | 18/34 (53%) |
| ALL | ||
| Number of patients | 29 | 18 |
| T-cell phenotype, no. (%) | 10 (34) | 5 (28) |
| Age, median (range) | 34 (18-74) | 29 (18-74) |
| WBC × 10−3, median (range) | 26 (0.8-600) | 46 (3-312) |
| Ph1chromosome, no. (%) | 7/28 (25) | 2/17 (12) |
| % blasts, median | 85 | 88 |
| CR by day 60, no. (%)1-155 | 11/21 (52%) | 9/12 (75%) |
AML = acute myelogenous leukemia; ALL = acute lymphocytic leukemia; WBC = white blood cell count; CR = complete response.
Includes patients treated with cytarabine, daunorubicin, and amsacrine56 as well as a small number of patients treated with cytarabine, daunorubicin, and etoposide with or without priming doses of GM-CSF56 or interleukin-3.57 In cases where cytokine was administered, samples harvested before cytokine were analyzed.
AHD, antecedent hematologic disorder, ie, myelodysplastic or myeloproliferative syndrome.
Leukemia occurring after prior cytotoxic chemotherapy for a nonhematologic malignancy.
Deletions involving chromosomes 5 or 7, trisomy 8, and complex karyotypes.
Number of CR ÷ (number of CR + NR).